× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En Fr

Our approach

adjuvant therapies

anticoagulant 2

anticoagulant, curative dose 5

anticoagulant, pre-admission 3

anticoagulant, prophylactic dose 4

anticoagulation, intermediate prophylactic dose 1

heparin at therapeutic dose 1

hydrogen-oxygen nebulizer

hyperbaric oxygen

pulmonary rehabilitation

respiratory support

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies 1

clarithromycine 2

Colchicine plus rosuvastatin 1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs 8

sodium aescinate

corticosteroids 7

dexamethasone 5

Dexamethasone 12mg 1

Hydrocortisone 4

low-dose corticosteroids

methylprednisolone 6

Immunostimulants drugs

anti-PD-1 antibody

convalescent plasma treatment 47

Early convalescent plasma. 1

immunoglobulin therapy 4

inactivated mycobacterium vaccine

high-dose IFN beta-1a 1

inhaled interferon

pegylated interferon-α2b 2

recombinant super-compound interferon rSIFN-co 1

SNG001 inhaled interferon beta 1

interferon / TFF2 1

peginterferon 2

neutralizing antibody

bamlanivimab monotherapy 2

bamlanivimab plus etesevimab 3

BRII-196 and BRII-198 (Brii Biosciences) 1

casirivimab and imdevimab (Ronapreve, REGN-COV2) 5

cilgavimab and tixagevimab (Evusheld)

equine polyclonal antibodies INM005 1

regdanvimab (CT-P59 Celltrion) 2

sotrovimab (Xevudy) 2

Immunosuppressants drugs

anti-interleukin-6

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

complement inhibitors

janus kinase (JAK) inhibitor

inhaled corticosteroids

Kinase inhibitors

acalabrutinib 2

Polyinosinic-Polycytidylic Acid

5-alpha-reductase inhibitors

proxalutamide 3

antiviral and associated therapy

ASC09/ritonavir

azithromycin 12

baloxavir marboxil 1

chloroquine and derivatives 1

hydroxychloroquine 46

danoprevir / ritonavir

darunavir cobicistat 1

darunavir/cobicistat plus chloroquine

Emtricitabine/tenofovir plus colchicine plus rosuvastatin 1

favipiravir plus interferon 1

hydroxychloroquine plus macrolides 7

azithromycin plus hydroxychloroquine 4

ivermectin plus doxycycline 3

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 9

Lopinavir/ritonavir plus hydroxychloroquine 1

lopinavir/ritonavir plus interferon ß-1a 1

lopinavir/ritonavir, ribavirin and interferon beta-1b 1

nirmatrelvir / ritonavir (Paxlovid) 1

oseltamivir plus chloroquin

sofosbuvir and daclatasvir 6

sofosbuvir and ledipasvir 2

tenofovir/emtricitabine 1

tranexamic acid

umifenovir (arbidol) 5

prone positioning

Drugs for acid related disorders

proton pump inhibitors (PPI) 6

2-deoxy-D-glucose (2-DG)

alpha lipoic acid 1

BLD-2660 (calpain inhibitor)

calcium channel blocker

camostat mesilate 1

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

kinin-kallikrein inhibitors

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

povidone-iodine 1

PUL-042 inhalation solution

pyridostigmine 1

Oral antidiabetic drugs

dapagliflozin 1

DPP-4 inhibitor

Renin-angiotensin-system-acting agents 7

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs) 3

angiotensin-(1-7)

discontinuation of ACEI/ARB 3

RAS blocker withdrawal

BCG vaccination

zinc plus vitamin c 1

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy -